Differences in RNA and microRNA Expression Between PTCH1- and SUFU-mutated Medulloblastoma

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Germline mutations in PTCH1 or SUFU genes activate the sonic hedgehog (SHH) pathway, leading to Gorlin syndrome and an elevated risk of SHH-subgroup medulloblastoma.
• Gorlin syndrome contraindicates radiotherapy due to basal cell carcinoma development, and existing SHH inhibitors are ineffective against SUFU-mutated medulloblastoma.
• Identifying molecular differences between PTCH1- and SUFU-mutated medulloblastomas is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate differential gene and microRNA expression between PTCH1-mutated and SUFU-mutated SHH medulloblastomas.
• To identify potential new therapeutic targets for SHH-subgroup medulloblastomas associated with Gorlin syndrome.
• To elucidate mechanisms underlying tumor behavior and relapse patterns in PTCH1- and SUFU-mutated medulloblastomas.

Main Methods:

• RNA and microRNA sequencing of tumors from two patients with germline Gorlin syndrome (one PTCH1 mutation, one SUFU mutation).
• Bioinformatics analysis to identify differential gene and microRNA expression.
• Validation of expression changes using quantitative reverse transcription PCR (qRT-PCR) and pathway analysis.

Main Results:

• The SUFU-mutated tumor showed lower expression of miR-301a-3p, miR-181c-5p, MMP11, and OTX2 compared to the PTCH1-mutated tumor.
• The SUFU-mutated tumor exhibited higher expression of miR-7-5p and lower expression of its target gene, GJB6 (connexin 30).
• Proposed mechanisms explain phenotypic differences and the tendency for local relapse in these tumor types.

Conclusions:

• The study identified distinct molecular signatures between PTCH1- and SUFU-mutated medulloblastomas.
• These findings provide a basis for developing novel, targeted treatment strategies for these specific medulloblastoma subtypes.
• Understanding these molecular differences is key to improving treatment outcomes and addressing therapeutic challenges in Gorlin syndrome-associated medulloblastomas.